

Effects of Pine Bark Extract on Attention-deficit Hyperactivity Disorder in Adults: A Randomized Double-blind Crossover Study

Cheng-Dien Hsu¹, Li-Hsuan Hsieh², Ya-Ling Chen², I-Cheng Lin³, Ying-Ru Chen³, Chih-Chi Chen³ and Suh-Ching Yang^{2,4,5*}

¹Department of Psychiatry, Taiwan Adventist Hospital, Taipei 10556, Taiwan

²School of Nutrition and Health Sciences, Taipei Medical University, Taipei 11031, Taiwan

³Department of Psychiatry, Hsuang Ho Hospital, New Taipei City 23455, Taiwan

⁴Research Center of Geriatric Nutrition, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan

⁵Nutrition Research Center, Taipei Medical University Hospital, Taipei 11031, Taiwan

Abstract

Aim: To investigate the effects of polyphenolic compound (PE) from pine bark on inattention, impulsivity and oxidative stress in adults with attention deficit hyperactivity disorder (ADHD).

Methods: It was a randomized, double-blind, crossover and placebo-controlled 10-weeks period study, including two interventional periods (4 weeks/period) and one washout period (2 weeks). Data were from 11 participants with attention deficit hyperactivity disorder (ADHD) at ages 35.1±9.6 years (2 male and 9 female). During the first interventional period, participants were received 2-3 capsule of PE from pine bark, which contain 25mg Oligopin® per capsule, or 2-3 capsule of placebo, which contains 25mg cellulose. Then, participants entered the washout period for 2 weeks. After 2 weeks of washout, the participants entered the second interventional period and crossed over to receive the supplementation which was different from the first interventional period. Neuropsychological assessment, antioxidative status, blood biochemical parameter and dietary intake were carried out.

Results: The item of hyperactivity-impulsivity in adult ADHD Self-Report Scale (ASRS) was significantly decreased; however the lipid peroxidation such as plasma 2-thiobarbituric acid-reactive substance and 8-isoprostane levels only showed the lower trend when participants received PE capsules. All blood biochemical parameters were normal in the interventional periods. Moreover, significantly lower carbohydrate intake was found during the PE supplementation period.

Conclusions: This study indicated that 4-week supplementation with pine bark extract significantly decreased the hyperactivity-impulsivity based on adult ASRS, which represented pine bark extract may have the potential for ameliorating the symptoms of ADHD; however plasma TBARS and 8-isoprotstnae levels only showed the decreased trend in ADHD adults.

Introduction

Attention deficit hypertension disorder (ADHD) is characterized by inattention, impulsivity and hyperactivity [1]. A mean worldwide prevalence of ADHD is 2.2% (range: 0.1-8.1%) which has been estimated in children and adolescents (aged <18 years). The mean prevalence of ADHD in adults (aged 18-44 years) from a range of countries in Asia, Europe, the Americas and the Middle East was reported as 2.8% (range: 0.6-7.3%) [2]. In Taiwan, the prevalence of ADHD was 19.8% for boys and 12.3% for girls in elementary students with a boy and girl ratio of 3:1 [3]. Moreover, the problems of inattention and hyperactivity continue to occur in adulthood in more than three-quarters of cases [4].

The etiology of ADHD is complicated, including genetic factors, the abnormal metabolism of neurotransmitters, heavy metal toxicity, food sensitivities, or nutritional problems etc. [5]. Recently, it is assumed that oxidative stress may play an important role in pathology of ADHD [6]. Therefore, antioxidant supplements have been reported to assist the classical treatment of ADHD by psychostimulants and antidepressants because of the side effects of these psych-medicaments [6].

The bark extract of French maritime pine (*Pinus pinaster*) contains abundant oligomeric procyanidins (OPCs) that are considered as the potent antioxidants with strong antioxidative capacities, such as catechin, epicatechin, gallic acid, caffeic acid, ferulic acid, p-coumaric acid, taxifolol, ferrulate glucoside etc. [7]. Heimann collected case reports about beneficial effects following treatment of polyphenolic

extract (PE) from pine bark in French children with ADHD [8]. Our previous study also showed that ADHD children who received 1 mg/kg BW/day of PE showed the improvement effects on inattention and impulsivity, and reduction of plasma lipid peroxidation levels during a 4-week experimental period [9]. Therefore, we hypothesized that PE also could improve symptoms of inattention and impulsivity in adults with ADHD, which are well-correlated with elevated antioxidative status. This study was carried out to verify this hypothesis.

Methods

Participant recruitment

The study was approved by the Taipei Medical University (TMU)-Joint Institutional Review Board (protocol ID: N201706026, ClinicalTrials.gov ID: NCT03368690). All procedures were conducted according to principles expressed in the *Declaration of Helsinki*. Written informed consent was obtained from all participants.

***Corresponding Author:** Dr Suh-Ching Yang, School of Nutrition and Health Sciences, Taipei Medical University, 250 Wu-Hsing Street, Taipei 11031, Taiwan. Tel: +886-2-2736-1661, Fax: +886-2-2737-3112; E-mail: sokei@tmu.edu.tw

Citation: Hsu CD, Hsieh LH, Chen YL, Lin IC, Chen YR, et al. (2020) Effects of Pine Bark Extract on Attention-deficit Hyperactivity Disorder in Adults: A Randomized Double-blind Crossover Study. Int J Clin Nutr Diet 6: 152. doi: <https://doi.org/10.15344/2456-8171/2020/152>

Copyright: © 2020 Hsu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication History:

Received: May 08, 2020

Accepted: June 24, 2020

Published: June 26, 2020

Keywords:

Polyphenolic extract from pine bark, Attention deficit/hyperactivity disorder, Oxidative stress

Recruitment was conducted in the psychiatric department of Taiwan Adventist Hospital, Hsuang Ho Hospital from September 2017 to June 2019. Participants, who were aged 20~64 years and attended a preliminary screening session using ASRS (Adult ADHD Self-Report Scale) score (more than 17), SPM+ (Raven's Standard Progressive Matrices Plus; excepted for D level), BDI-II (Beck Depression Inventory, second edition) score (less than 13) and BAI (Beck Anxiety Inventor, second version) score (less than 7). Finally, participants were recruited into the study after being diagnosed with ADHD by a psychiatrist using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). The exclusion criteria were as follows: medications, dietary supplements, or neurological disorders which included brain or other central nervous system functions such as epilepsy and intellectual disabilities. Mental disorders (autism, psychosis, bipolar disorder, major depressive disorder, anxiety, personality disorder, conduct disorder, tic disorder etc.) and chronic diseases (liver, kidney, gastrointestinal, cardiovascular diseases, etc.) were also listed as exclusion criteria.

Intervention

It was a randomized, double-blind, placebo-controlled crossover study. The randomization was performed by drawing lots. Neither the participants nor researchers knew which person was in which group. There were two experimental periods such as including placebo and PE supplementation separated by 2-week washout period. In the first experimental period, ADHD subjects were randomly provided with placebo or PE supplementation for 4 weeks. After the washout period, all ADHD subjects were provided with the other supplement in the second period for 4 weeks. The dosage of PE capsules was modified from the previous literature [10-12]. ADHD participants were provided 2 capsules (body weight more than 40 kg and less than 60 kg) or 3 capsules (body weight more than 60 kg) of PE (each capsule contained 50 mg PE) per day. One capsule contained 50 mg PE (Oligopin®, DRT, Dax, France) including of 67%~75% OPCs, 4%~10% catechin, 4%~10% ferrulate glucoside, 3%~8% taxifoliol glucoside, 1%~5% ferulic acid etc. [7]. Placebo supplements contained maltodextrin and magnesium stearate.

Measurements

Psychological examination

A psychological examination was carried out at baseline, 4, 7 and 10 weeks. The evaluation process was assisted by psychiatrists. ASRS

and continue performance test III (CPT-III) were used to evaluate the inattention and impulsivity in ADHD participants [13,14]. ASRS included 18 questions which 1 to 9 is for the evaluation of inattention and 10 to 18 is for the evaluation of hyperactivity and impulsivity. The score ranges from "0" (never) to "4" (very often). The higher score indicates higher levels of ADHD symptom using 17 as a cut-off point for ADHD diagnosis [13]. The Conners' CPT-III was also used in this study to evaluate ADHD symptoms. It is a 14-min computerized assessment tool which involves rapid presentation of visual stimuli. During the test, respondents are required to respond when any letter appears, except the non-target letter "X" [14]. Wechsler Memory Scale, 3rd edition (WMS-III) was used to assess immediate memory, working memory and delay memory for the ADHD participants [15,16]. Wisconsin Card Sorting Test™, computer version 4 (WCST-CV4) was used to evaluate executive functions [17].

Blood collection and analysis

The blood of participants was collected after 8 h of fasting at baseline, 4 and 10 weeks in TMU Hospital. The ratio of erythrocytic reduced form of glutathione (GSH) to the disulfide form (GSSG) was measured as an indicator of antioxidative capacity according to the previous study [18]. The GSH/GSSG ratio was calculated as (total GSH - 2GSSG) / GSSG. The lipid peroxidation of plasma samples was determined with a commercial enzyme-linked immunosorbent assay (ELISA) kit including 2-thiobarbituric acid-reactive substance (TBARS) (no. 10009055, Cayman Chemical, Ann Arbor, MI, USA) and 8-isoprostane (no. 516,351, Cayman Chemical, Ann Arbor, MI, USA) [19,20].

In order to monitor the safety of supplements, biochemical parameters were determined including blood cell analysis, liver function indicators (aspartate transaminase (AST) and alanine transaminase (ALT) activities), blood lipid profiles, nutritional status indicator, renal function indicator and iron nutrition status. All items were evaluated with an automated clinical chemistry analyzer (SYNCHRON CX System 7170, Hitachi, Tokyo, Japan).

Dietary intake assessment

Three-day dietary record was performed in every period. All data were analyzed by Nutrients Analysis Software (2018) established by the Taiwan Dietitian Association. Participants were instructed by dietitians, such as meal portion size and cooking method etc.

	B	P	PE	p value		
				B x P	B x PE	P x PE
Sex (M/F)	2 / 9	2 / 9	2 / 9			
Age (year)	35.1 ± 9.6	35.3 ± 9.6	35.3 ± 9.6			
Height(cm)	162.6 ± 8.9	162.6 ± 8.9	162.6 ± 8.9			
Body weight(kg)	65.9 ± 16.4	66.1 ± 16.7	66.3 ± 16.9	0.697	0.311	0.604
Fat mass (%)	32.3 ± 12.2	33.5 ± 12.6*	32.5 ± 11.6	0.042	0.785	0.176
Body mass index (kg/m ²)	24.9 ± 6.2	25.0 ± 6.1	25.1 ± 6.3	0.785	0.348	0.540
Systolic blood pressure (mmHg)	117.7 ± 15.8	113.5 ± 13.0	114.6 ± 16.5	0.262	0.357	0.799
Diastolic blood pressure (mmHg)	79.4 ± 12.1	78.5 ± 13.3	79.9 ± 13.6	0.734	0.858	0.633

Table 1: Effects of polyphenolic compounds from pine bark extract on the anthropometric assessment in attention-deficit hyperactive disorder participants. Values are expressed as the mean ± SD. An asterisk (*) indicates a significant difference compared to group B ($p < 0.05$). B: baseline, before supplementation; P: placebo, 4-week supplementation with maltodextrin and magnesium stearate; PE: 4-week supplementation of polyphenolic compounds from pine bark extract; BMI: body-mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure.

Statistical analysis

Statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA). All values are expressed as the mean \pm standard deviation (SD). Differences among groups were compared by the Wilcoxon sign-rank test. *P* value less than 0.05 was considered statistically significant.

Results

General characteristics

Eleven ADHD subjects, including 2 males and 9 females, were fully engaged in this study (Figure 1), and their general characteristics are shown in Table 1. The mean age at baseline was 35.1 ± 9.6 years. According to the criteria of obesity in Taiwan (BMI > 27; fat mass > 25% for male, > 30% for female), participants were overweight based on BMI and obesity based on fat mass. Blood pressure values were within normal ranges under 120/80 mmHg. When compared to baseline, the fat mass of participants was significantly increased after placebo supplementation.

Effect of PE supplementation on the psychological examination

As shown in Table 2 no difference was found in the inattention item among groups. However, the item of hyperactivity and impulsivity was significantly decreased in PE groups than that of baseline ($p < 0.05$). After 4 weeks of supplementation with PE and the placebo, results of CPT-III are shown in Table 3. No significant difference was found among groups. Only the T-score of commissions showed the lower trend in PE supplementation period (lower values reflected more desirable scores). For the evaluation of memory function, there are some items were significantly increased including word test I and auditory memory span, whereas verbal paired associates I was significantly increased during placebo supplementation period compared to baseline (Table 4). However, no difference was found during PE supplementation period. On the other hand, there are no differences among groups in WCST scores for the evaluation of executive functions (Table 5).




Figure 1: Flow chart of subject enrollment and the intervention.

Fourteen participants attended a preliminary screening session using Adult ADHD Self-Report Scale (more than 17), Raven's Standard Progressive Matrices Plus (excepted for D level), Beck Depression Inventory score was (less than 13) and Beck Anxiety Inventor score (less than 7). Twelve participants were recruited and were randomly divided into a placebo group and a pine bark extract (PE) group. After placebo or PE supplementation for 4 weeks, there was a two-week washout period, then all participants were crossed over to the different supplementation for another 4 weeks. Only one participant was excluded during the first supplementation period due to the emotional problem. Placebo group, 4-week supplementation with maltodextrin and magnesium stearate; PE, 4-week supplementation of polyphenolic compounds from pine bark extract.

	B	P	PE	p value		
				B x P	B x PE	P x PE
Inattention	24.3 ± 5.08	22.7 ± 4.67	22.2 ± 3.89	0.246	0.103	0.625
Hyperactivity-impulsivity	19.3 ± 5.31	17.3 ± 4.88	16.5 ± 4.72*	0.161	0.018	0.245

Table 2: Effects of polyphenolic compounds from pine bark extract on the Adult ADHD Self-Report Scale in attention-deficit hyperactive disorder participants. Values are expressed as the mean ± SD. An asterisk (*) indicates a significant difference compared to group B ($p < 0.05$). B: baseline, before supplementation; P: placebo, 4-week supplementation with maltodextrin and magnesium stearate; PE: 4-week supplementation of polyphenolic compounds from pine bark extract.

	T-score			p value		
	B	P	PE	B x P	B x PE	P x PE
Inattention						
Detectability	47.5 ± 9.4	46.0 ± 7.6	45.5 ± 9.8	0.508	0.460	0.821
Omissions	46.2 ± 4.1	46.0 ± 2.1	47.3 ± 4.9	0.829	0.556	0.387
Commissions	52.2 ± 11.5	48.2 ± 9.6	47.3 ± 9.1	0.138	0.099	0.672
HRT	47.8 ± 7.3	49.4 ± 8.8	51.8 ± 9.0	0.321	0.053	0.057
HRT-SD	47.9 ± 10.4	46.1 ± 7.8	50.1 ± 12.0	0.281	0.342	0.060
Variability	46.6 ± 7.4	45.0 ± 5.0	47.4 ± 10.1	0.427	0.807	0.363
Impulsivity						
Commissions	52.2 ± 11.5	48.2 ± 9.6	47.3 ± 9.1	0.138	0.099	0.672
HRT	47.8 ± 7.3	49.4 ± 8.8	51.8 ± 9.0	0.321	0.053	0.057
Perseverations	48.1 ± 3.1	47.3 ± 3.2	48.5 ± 5.1	0.419	0.797	0.396
Sustained attention						
HRT-BC	48.3 ± 8.9	51.5 ± 6.2	53.5 ± 14.7	0.270	0.383	0.634
Vigilance						
HRT-ISI-C	55.4 ± 11.1	57.0 ± 9.3	57.9 ± 6.7	0.262	0.228	0.428

Table 3: Effects of polyphenolic compounds from pine bark extract on CPT-III in attention-deficit hyperactive disorder participants. Values are expressed as the mean ± SD. B: baseline, before supplementation; P: placebo, 4-week supplementation with maltodextrin and magnesium stearate; PE: 4-week supplementation with polyphenolic compounds from pine bark extract; CPT-III: continuous performance test III; HRT: hit reaction time; HRT-SD: hit reaction time-standard deviation; HRT-BC: hit reaction time-block change; HRT-ISI-C: hit reaction time-inter-stimulus interval-change.

	B	P	PE	p value			
				B x P	B x PE	P x PE	
Immediate memory subtests							
Word test I	word list I -recall score	10.4 ± 3.7	14.1 ± 4.5	13.5 ± 3.4	0.089	0.051	0.761
	total recall scores	9.9 ± 3.4	14.0 ± 3.3*	12.8 ± 3.4	0.020	0.088	0.401
	learning ratio	9.4 ± 2.2	7.4 ± 4.4	7.8 ± 3.5	0.214	0.068	0.875
Verbal paired associates I	total recall scores I	10.6 ± 3.6	14.4 ± 1.7	13.3 ± 2.6	0.017	0.084	0.091
	learning ratio	9.6 ± 3.0	7.1 ± 2.3*	8.1 ± 2.7	0.037	0.157	0.651
Working memory subtests							
Spatial digit Span	forward	9.8 ± 2.4	9.2 ± 1.3	9.6 ± 2.2	0.396	1.000	0.411
	backward	10.5 ± 2.3	9.5 ± 2.0	10.5 ± 1.9	0.296	1.000	0.167
	total scores	12.1 ± 3.5	12.8 ± 3.3	13.2 ± 3.3	0.181	0.145	0.588
Auditory memory span	forward	10.9 ± 2.5	11.9 ± 2.3*	12.1 ± 1.6	0.049	0.071	0.756
	backward	12.0 ± 2.6	12.4 ± 2.7	12.4 ± 2.9	0.506	0.602	0.846
Delay memory subtests							
Word test II	recognition test	10.0 ± 3.0	10.6 ± 2.0	11.3 ± 2.8	0.404	0.290	0.759
	retention (%)	9.8 ± 2.9	11.7 ± 2.2	9.5 ± 3.0	0.103	0.750	0.058
Verbal paired associates II	retention (%)	11.2 ± 1.7	9.7 ± 2.8	9.5 ± 2.0	0.224	0.184	0.934

Table 4: Effects of polyphenolic compounds from pine bark extract on Wechsler Memory Scale-III in attention-deficit hyperactive disorder participants. Values were expressed as the mean ± SD. An asterisk (*) indicates a significant difference compared to group B ($p < 0.05$). B: baseline, before supplementation; P: placebo, 4-week supplementation of maltodextrin and magnesium stearate; PE: 4-week supplementation of polyphenolic compounds from pine bark extract.

Effect of PE supplementation on the antioxidative status

After 4 weeks of PE supplementation, the erythrocytic GSH/GSSG ratio didn't change (Table 6). The plasma TBARS and 8-isoprostane levels showed the lower trend after PE supplementation (Table 6), although the significance wasn't found.

Effect of PE supplementation on biochemical parameters

Changes in biochemical parameters of ADHD participants during the experimental period are shown in Table 7. During the placebo supplementation period, the total cholesterol and LDL-cholesterol levels were significantly increased when compared to baseline ($p < 0.05$). On the other hand, during the PE supplementation period, the plasma creatinine level was significantly higher than during the placebo supplementation period ($p < 0.05$), and the potassium level was also significantly higher compared to the baseline ($p < 0.05$). PE supplementation period showed the significantly lower platelet number than placebo supplementation did ($p < 0.05$). However, all values were still within normal ranges.

Effect of PE supplementation on dietary intake

Dietary intake during the experimental period is shown in Table 8. When compared to placebo supplementation period, the carbohydrate intake was significantly decreased in PE supplementation period ($p < 0.05$).

Discussion

Physiological status

As shown in Table 1, ADHD participants maintained physiological status during the experiment period, although fat mass was significantly increased during placebo supplementation period (Table 1). For monitoring the safety of supplementation, blood biochemical

parameters were measured (Table 7). Higher plasma creatinine and potassium levels were found during PE supplementation, but these values were still within the normal range. In addition, participants did not report any adverse events such as nausea, vomiting, poor appetite, etc. The 50% lethal dose (LD50) of PE was > 2000 mg/kg BW, and the no-observed-adverse effect level (NOAEL) was 1000 mg/kg BW based on a 90-day study of male and female rats [21]. Only one ADHD patient was reported to have moderate gastric discomfort after PE supplementation in the previous study (1 mg/kg BW/day) [10].

Neuropsychological function

ASRS was developed in conjunction with the World Health Organization (WHO) and the Workgroup on Adult ADHD to help professionals to screen adult ADHD. In this study, ASRS also used to screen the adult ADHD and used as an indicator for evaluating the beneficial effects of PE. In this study, CPT-III was also used to evaluate inattention and impulsivity in ADHD participants in order to quantitatively analyze data [22]. Tenebaum et al. indicated that no statistically significant difference was detected for the self-reported data including ASRS and CPT after 3-week PE supplementation [23]. In this study, the item of hyperactivity-impulsivity in ASRS was significantly, but no improvement was found in CPT-III, WMS-III, and WCST-IV after 4-week PE supplementation. The length of treatment and dosage of supplements may have contribute the absence of significant differences on the improvement of ADHD symptoms.

Antioxidative status

Several works on different levels including cell cultures, experimental animal models, and human studies which was deal with effects of PE on brain functions or mental health [24]. These results indicated that PE inhibited oxidative stress, such as increased GSH/GSSG ratio by normalizing catecholamine levels in ADHD subjects, which may reduce hyperactivity and increase attention [25]. In this study, after 4-week PE supplementation, only plasma TBARS and

	B	P	PE	p value		
				B x P	B x PE	P x PE
Total errors (%)	51.8 ± 4.0	54.0 ± 4.5	54.5 ± 4.4	0.255	0.085	0.816
Perseverative responses (%)	52.3 ± 6.2	57.2 ± 10.2	54.5 ± 6.5	0.193	0.178	0.482
Perseverative errors (%)	53.3 ± 5.3	57.4 ± 8.5	54.4 ± 5.8	0.192	0.351	0.345
Non-perseverative errors (%)	51.2 ± 5.6	51.9 ± 4.6	53.5 ± 4.9	0.754	0.331	0.440
Conceptual level responses (%)	51.5 ± 4.7	53.6 ± 4.8	54.2 ± 4.0	0.333	0.136	0.766

Table 5: Effects of polyphenolic compounds from pine bark extract on Wisconsin Card Sorting Test-IV in attention-deficit hyperactive disorder participants. ¹Values were expressed as the mean ± SD. B: baseline, before supplementation; P: placebo, 4-week supplementation of maltodextrin and magnesium stearate; PE: 4-week supplementation of polyphenolic compounds from pine bark extract.

	B	P	PE	p value		
				B x P	B x PE	P x PE
Erythrocytic GSH/GSSG ratio	3.8 ± 1.7	4.3 ± 2.1	4.3 ± 1.8	0.466	0.355	0.964
Plasma TBARS (µM)	8.7 ± 4.1	9.6 ± 7.5	6.8 ± 4.8	0.100	0.880	0.168
Plasma 8-isoprostane (pg/mL)	52.1 ± 23.4	54.3 ± 25.7	43.8 ± 33.8	0.834	0.398	0.332

Table 6: Effects of polyphenolic compounds from pine bark extract on the ratio of erythrocytic reduced glutathione/oxidized glutathione in attention-deficit hyperactive disorder participants. Values are expressed as the mean ± SD. B: baseline, before supplementation; P: placebo, 4-week supplementation with maltodextrin and magnesium stearate; PE: 4-week supplementation with polyphenolic compounds from pine bark extract; GSH: reduced glutathione; GSSG: oxidized glutathione; TBARS: 2-thiobarbituric acid-reactive substance.

	B x P	B x PE	P x PE	p value		
				B	P	PE
Liver function						
AST/SGOT (U/L)	21.7 ± 8.3	23.7 ± 12.6	21.6 ± 7.7	0.576	0.914	0.512
ALT/SGPT (U/L)	20.6 ± 11.7	28.5 ± 25.2	18.6 ± 8.0	0.346	0.285	0.200
Bilirubin-Total (mg/dL)	0.7 ± 0.2	0.7 ± 0.2	0.6 ± 0.3	0.819	0.396	0.395
Kidney function						
BUN (mg/dL)	12.0 ± 3.0	13.3 ± 3.1	11.9 ± 2.9	0.121	0.855	0.097
Creatinine (mg/dL)	0.78 ± 0.14	0.76 ± 0.14	0.81 ± 0.15 [†]	0.164	0.174	0.008
Uric acid (mg/dL)	4.9 ± 1.6	5.1 ± 1.6	4.8 ± 1.4	0.336	0.479	0.115
Sodium (meq/L)	140.2 ± 2.0	139.2 ± 1.4	139.1 ± 0.9	0.093	0.082	0.821
Potassium (meq/L)	4.8 ± 0.5	5.0 ± 0.6	5.4 ± 0.7*	0.201	0.014	0.152
Protein nutrition status						
Protein,total (g/dL)	7.3 ± 0.4	7.4 ± 0.3	7.3 ± 0.4	0.211	0.689	0.747
Albumin (g/dL)	4.4 ± 0.3	4.5 ± 0.3	4.1 ± 1.0	0.074	0.431	0.257
Globulin (g/dL)	2.9 ± 0.3	2.9 ± 0.3	2.9 ± 0.4	1.000	1.000	1.000
Lipid profile						
Triglyceride (mg/dL)	99.3 ± 58.1	90.6 ± 40.0	78.3 ± 28.6	0.550	0.146	0.066
Cholesterol (mg/dL)	173.9 ± 28.2	192.2 ± 28.0*	184.9 ± 27.0	0.034	0.232	0.247
HDL-Cho (mg/dL)	55.9 ± 11.2	60.4 ± 10.5	58.7 ± 10.5	0.310	0.140	0.324
LDL-Cho (mg/dL)	100.1 ± 28.3	117.0 ± 27.6*	111.7 ± 24.4	0.019	0.164	0.349
T-CHO/HDL (ratio)	3.2 ± 0.8	3.3 ± 0.7	3.2 ± 0.7	0.583	0.902	0.939
Hematology						
WBC (10 ³ /μL)	6.5 ± 2.1	6.6 ± 2.2	6.6 ± 2.0	0.784	0.884	0.955
RBC (10 ⁶ /μL)	4.9 ± 0.7	4.9 ± 0.7	4.8 ± 0.7	0.752	0.103	0.109
Hemoglobin (g/dL)	13.5 ± 1.5	13.6 ± 1.5	13.3 ± 1.4	0.509	0.088	0.077
Hematocrit (%)	40.8 ± 3.7	41.1 ± 4.0	40.2 ± 3.5	0.591	0.072	0.080
MCV (fL)	84.8 ± 8.5	84.9 ± 8.5	84.7 ± 8.1	0.881	0.698	0.626
MCH (pg)	28.0 ± 3.4	28.0 ± 3.4	28.0 ± 3.6	0.536	0.806	0.729
MCHC (g/dL)	32.9 ± 1.1	33.0 ± 1.2	33.0 ± 1.3	0.850	0.803	1.000
Platelet (10 ³ /μL)	298.1 ± 155.9	310.0 ± 96.9	293.3 ± 99.4 [†]	0.634	0.835	0.028
Neutrophil Seg. (%)	59.5 ± 7.6	60.5 ± 6.6	59.5 ± 6.5	0.522	1.000	0.634
Lymphocyte (%)	31.4 ± 7.1	30.8 ± 6.2	31.8 ± 6.4	0.718	0.846	0.618
Monocyte (%)	5.6 ± 2.0	5.6 ± 1.6	5.5 ± 1.6	0.934	0.854	0.934
Eosinophil (%)	2.9 ± 2.4	2.5 ± 1.8	2.7 ± 1.8	0.090	0.529	0.465
Basophil (%)	0.7 ± 0.4	0.6 ± 0.3	0.6 ± 0.3	0.420	0.186	0.690
Iron status						
Iron (μg/dL)	97.8 ± 49.1	85.8 ± 52.3	82.8 ± 45.4	0.503	0.265	0.783
TIBC (μg/dL)	334.2 ± 52.0	340.6 ± 64.9	340.1 ± 72.6	0.426	0.486	0.936
Ferritin (ng/mL)	70.2 ± 83.5	62.3 ± 63.3	56.7 ± 53.2	0.331	0.294	0.380

Table 7: Effects of polyphenolic compounds from pine bark extract on biochemical parameters in attention-deficit hyperactive disorder participants. Values are expressed as the mean ± SD. An asterisk (*) indicates a significant difference compared to group B ($p < 0.05$). B: baseline, before supplementation; P: placebo, 4-week supplementation with maltodextrin and magnesium stearate; PE: 4-week supplementation with polyphenolic compounds from pine bark extract; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TC: total cholesterol; WBCs: white blood cells; RBCs: red blood cells; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; TIBC: total iron-binding capacity.

	P	PE	p value
Total Energy(kcal)	1542.1 ± 363.9	1680.1 ± 326.6	0.323
Carbohydrates (% of kcal)	50.2 ± 5.1	47.8 ± 4.2*	0.023
Protein (% of kcal)	15.6 ± 2.0	17.4 ± 3.2	0.383
Fat (% of kcal)	36.4 ± 3.5	36.3 ± 3.5	0.630
Vitamin B1 (mg)	0.7 ± 0.5	1.0 ± 0.6	0.672
Vitamin B2 (mg)	1.1 ± 0.3	1.3 ± 0.4	0.844
Vitamin B6 (mg)	1.2 ± 0.4	1.3 ± 0.3	0.349
Vitamin A (µg/RE)	977.9 ± 731.9	723.5 ± 234.8	0.713
Vitamin C (mg)	77.1 ± 55.0	59.9 ± 22.8	0.174
Vitamin E(α-TE/mg)	12.7 ± 10.9	15.4 ± 19.3	0.092
Sodium (mg)	1755.2 ± 701.8	1865.7 ± 742.6	0.127
Calcium (mg)	555.3 ± 271.0	571.4 ± 212.4	0.169
Magnesium(mg)	220.8 ± 82.3	387.8 ± 468.4	0.327
Iron (mg)	10.5 ± 3.5	9.6 ± 1.7	0.638
Zinc (mg)	8.3 ± 2.7	9.5 ± 2.9	0.207

Table 8. Dietary intake of the 3-day dietary records in each period attention-deficit hyperactive disorder participants.

Values are expressed as the mean ± SD. B: baseline, before supplementation; P: placebo, 4-week supplementation with maltodextrin and magnesium stearate; PE: 4-week supplementation with polyphenolic compounds from pine bark extract; RE: retinol equivalent; TE: tocopherol equivalent.

8-isoprostane decreased slightly compared to the baseline and placebo but did not reach significance. The relatively small number, dosage and the length of supplementation may be the possible reasons for unobvious influences. Additionally, more evaluation indicators for oxidative stress is necessary for the future study, such as total oxidative status (TOS), total antioxidant status (TAS) and total antioxidant capacity (TAC) and could be useful for identification of redox imbalance in patients with ADHD.

Dietary intake

Dietary intake did not change during the entire experimental period except lower carbohydrate intake during PE supplementation period (Table 8). Previous research pointed out that dietary intake and nutrition-related factors are associated with symptoms of ADHD [26-28]. Nutrient insufficiency may affect neurocognitive abilities, for example iron as a coenzyme of dopamine and norepinephrine, and zinc as an endogenous neuromodulator in synaptic transmission [29]. In this study, it was also indicated that higher fat intake and lower intake of vitamin A, calcium and zinc compared to DRIs in Taiwan. Therefore, determining food consumption and dietary patterns of ADHD children may be helpful in clarifying relationships between nutritional factors and ADHD symptoms.

Strengths and limitations

This study evaluated improvements in ADHD symptoms using both an administered questionnaire and quantitative analyses after PE supplementation. Moreover, all ADHD participants were diagnosed without other psychiatric comorbidities and medical treatment. However, this study still has several limitations. First, the sample size was small because of the complicated screening process and assessments. Second, compliance of taking the supplement was 80.2%, which should be increased in future studies. Lastly, more oxidative damage biomarkers should be measured in future study.

Conclusions

This study indicated that 4-week supplementation with pine bark extract significantly decreased the hyperactivity-impulsivity based on adult ADHD Self-Report Scale, which represented pine bark extract may have the potential for ameliorating the symptoms of ADHD; however plasma TBARS and 8-isoprostane levels only showed the decreased trend in ADHD adults.

Conflict of Interest

The authors declare no conflicts of interests. Neither Formosa Produce Corporation (Taipei, Taiwan) nor DRT (Dax Cedex, French) has any further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Acknowledgement

We thank Formosa Produce Corporation (Taipei, Taiwan) for providing the funds and DRT (Dax Cedex, French) for supplying the pine bark extract. We also thank Dr. Yannick Piriou who provided the professional information and analyzed the composition of the pine bark extract.

Author's Contribution

Cheng-Dien Hsu and Suh-Ching Yang designed the study. Cheng-Dien Hsu recruited ADHD participants, and Li-Hsuan Hsieh contacted ADHD participants. The psychiatric evaluation was conducted by Cheng-Dien Hsu, I-Cheng Lin, Ying-Ru Chen and Chih-Chi Chen. Li-Hsuan Hsieh and Ya-Ling Chen also completed blood measurements and statistical analysis of the data. Suh-Ching Yang wrote the manuscript.

References

1. Rowland AS, Lesesne CA, Abramowitz AJ (2002) The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. *Ment Retard Dev Disabil Res Rev* 8: 162-170.
2. Fayyad J, Sampson NA, Hwang I, Adamowski T, Gaxiola SA, et al. (2017) The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. *Atten Defic Hyperact Disord* 9: 47-65.
3. Huang CLC, Chu CC, Cheng TJ, Weng SF (2014) Epidemiology of treated attention-deficit/hyperactivity disorder (ADHD) across the lifespan in Taiwan: a nationwide population-based longitudinal study. *PLoS one* 9: e95014.
4. Barkley RA, Fischer M, Smallish L, Fletcher K (2002) The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. *J Abnorm Psychol* 111: 279-289.
5. Wilens TE, Biederman J, Spencer TJ (2002) Attention deficit/hyperactivity disorder across lifespan. *Annu Rev Med* 53: 113131.
6. Joseph N, Zhang-James Y, Perl A, Faraone SV (2015) Oxidative stress and ADHD: a meta-analysis. *J Atten Disord* 19: 915-924.
7. Segal L, Penman M, Piriou Y (2018) Evaluation of the systemic toxicity and mutagenicity of OLIGOPIN®, procyanidolic oligomers (OPC) extracted from French Maritime Pine Bark extract. *Toxicol Rep* 5: 531-541.
8. Heimann SW (1999) Pycnogenol for ADHD? *J Am Acad ChildAdolesc Psychiatry* 38: 357-358.
9. Chen YR, Su YJ, Piriou Y, Yang SC (2017) Effects of polyphenolic extract from pine bark on the improvement of attention deficit/hyperactivity disorder in children and adolescent. *Int J Clin Nutr Diet* 3: 116-119.

10. Chovanová Z, Muchová J, Sivoňová M, Dvořáková M, Žitňanová I, et al. (2006) Effect of polyphenolic extract, Pycnogenol®, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. *Free Radic Res* 40: 1003-1010.
11. Trebatická J, Kopasová S, Hradečná Z, Činovský K, Škodáček I, et al. (2006) Treatment of ADHD with French maritime pine bark extract, Pycnogenol®. *Eur Child Adolesc Psychiatry* 15: 329-35.
12. Dvořáková M, Ježová D, Blažíček P, Trebatická J, Škodáček I, et al. (2007) Urinary catecholamines in children with attention deficit hyperactivity disorder (ADHD): modulation by a polyphenolic extract from pine bark (Pycnogenol®). *Nutr Neurosci* 10: 151-157.
13. Kessler RC, Adler L, Ames M, Demler O, Faraone S, et al. (2005) The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. *Psychol Med* 35: 245-256.
14. Conners KC, Staff M (2015) CPT III: Conners' Continuous Performance Test III: Multi-Health Systems North Tonawanda, New York, NY, US.
15. Wechsler D (1997) WMS-III: Wechsler memory scale administration and scoring manual: Psychological Corporation, New York, NY, US.
16. Tulskey DS, Chiaravalloti ND, Palmer BW, Chelune GJ (2003) The Wechsler Memory Scale, Third Edition: A new perspective. In *Clinical interpretation of the WAIS-III and WMS-III*. Academic Press, Cambridge, MA, US.
17. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G, et al. (1993) *Wisconsin Card Sorting Test Manual: Revised and Expanded*. Psychological Assessment Resources, Odessa, FL, USA.
18. Griffith OW (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. *Anal Biochem* 106: 207-212.
19. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem* 95: 351-358.
20. Reilly MP, Barry P, Lawson JA, Fitz Gerald G (1997) Urinary 8-epi PGF2 α : An index of oxidant stress in vivo. *Fibrinolysis Proteol* 11: 81-84.
21. Segal L, Penman M, Piriou Y (2018) Evaluation of the systemic toxicity and mutagenicity of OLIGOPIN®, procyanidolic oligomers (OPC) extracted from French Maritime Pine Bark extract. *Toxicol Rep* 5: 531-541.
22. Hall CL, Valentine AZ, Groom MJ, Walker GM, Sayal K, et al. (2016) The clinical utility of the continuous performance test and objective measures of activity for diagnosing and monitoring ADHD in children: a systematic review. *Eur Child Adolesc Psychiatry* 25: 677-699.
23. Tenenbaum S, Paull JC, Sparrow EP, Dodd DK, Green L, et al. (2002) An experimental comparison of Pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). *J Atten Disord* 6: 49-60.
24. Trebatická J, Ďuračková Z (2015) Psychiatric disorders and polyphenols: can they be helpful in therapy? *Oxid Med Cell Longev* 2015: 248529.
25. Rucklidge JJ, Johnstone J, Kaplan BJ (2009) Nutrient supplementation approaches in the treatment of ADHD. *Expert Rev Neurother* 9: 461-476.
26. Millichap JG, Yee MM (2012) The diet factor in attention-deficit/hyperactivity disorder. *Pediatrics* 129: 330-337.
27. Del-Ponte B, Callo G, Cruz S, Grellert M, Santos IS, et al. (2019) Dietary patterns and attention deficit/hyperactivity disorder (ADHD): A systematic review and meta-analysis. *J Affect Disord* 252: 160-173.
28. McCann D, Barrett A, Cooper A, Crumpler D, Dalen L, et al. (2007) Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. *Lancet* 370: 1560-1567.
29. Takeda A (2001) Zinc homeostasis and functions of zinc in the brain. *Bio Metals* 14: 343-351.